We develop and localise cost-effectiveness models to support value communication, regulatory and HTA submissions.

We translate complex clinical data into robust QALY-based evidence, providing the specific utility justification required for positive HTA recommendations.

We articulate the comprehensive financial return on investment for your intervention, presenting a decisive, monetised value case to secure budget allocation from diverse stakeholders.

We project short & long-term budget impact using population, uptake, and cost parameters to inform affordability, funding and procurement planning.

We strategically de-risk your development pipeline by leveraging early economic models to define the precise evidence requirements for future HTA success and commercial viability, ensuring the prospective capture of data required for reimbursement.

We ensure your global value proposition resonates locally, adapting core economic models to meet the specific, nuanced evidence standards of local HTA agencies and secure market-by-market access.

We harness sophisticated survival analysis techniques to reliably extrapolate long-term outcomes from interim trial data, substantiating the enduring clinical and economic value essential for HTA submissions. Our methodology is not only statistically sound but clinically plausible and fully defensible under HTA scrutiny.